SCHEMBL3830265

SCHEMBL3830265

CCN(CC(=O)O)c1cccc(C#N)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.47
KCNA5 P22460 1/20 0.47
GFER P55789 1/20 0.46
FFAR1 O14842 3/20 0.45
ALDH1A1 P00352 2/20 0.42
CYP3A4 P08684 1/20 0.42
MAOB P27338 1/20 0.42
MCHR1 Q99705 1/20 0.42
FFAR4 Q5NUL3 1/20 0.41
GSK3B P49841 2/20 0.41
MEP1A Q16819 1/20 0.41
MEP1B Q16820 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
THRB P10828 1/20 0.40
KMT2A Q03164 1/20 0.40
MMP12 P39900 1/20 0.40
MMP13 P45452 1/20 0.40
LMNA P02545 1/20 0.39
PGR P06401 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6982499 0.89 KCNN4 (0.54) KCNN4KCNA5GFERFFAR1MAOB
SCHEMBL8650222 0.84 ALDH1A1 (0.53) KCNN4KCNA5GFERALDH1A1CYP3A4
SCHEMBL8120082 0.84 FFAR1 (0.45) KCNN4KCNA5GFERFFAR1MAOB
SCHEMBL6982511 0.83 CRHBP (0.52) KCNN4KCNA5FFAR1MAOBFFAR4
SCHEMBL8106455 0.82 KCNN4 (0.43) KCNN4KCNA5GFERFFAR1MAOB
SCHEMBL7056650 0.82 KCNN4 (0.45) KCNN4KCNA5GFERFFAR1MAOB
SCHEMBL7057421 0.82 FFAR1 (0.47) KCNN4KCNA5FFAR1MAOBMCHR1
SCHEMBL8117060 0.82 FFAR1 (0.42) KCNN4KCNA5FFAR1MAOBFFAR4
SCHEMBL8376226 0.81 HCRTR2 (0.44) GFERALDH1A1MAOBKDM4EMEN1
SCHEMBL9779957 0.79 FFAR1 (0.50) KCNN4KCNA5FFAR1ALDH1A1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946508-B1 NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS BRISTOL MYERS SQUIBB PHARMA CO (US) 2009-09-23 EP disclosed
US-6548512-B1 Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-04-15 US disclosed
US-6020357-A CARDIOVASCULAR DISORDERS; ANTCOAGULANTS DUPONT PHARMACEUTICALS COMPANY (US) 2000-02-01 US disclosed
EP-0946508-A1 NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS Du Pont Pharmaceuticals Company (US) 1999-10-06 EP disclosed
WO-1998028269-A1 NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1998-07-02 WO disclosed